speaker
Elliot
Conference Call Operator

Hello, everybody, and welcome to the Q3 2026 PEPFAR Pharmaceutical Industries Earnings Conference call. My name is Elliot, and I'll be coordinating your call today. If you would like to ask a question during today's event, please press star followed by one on your telephone keypad. Today, we ask you to limit yourself to one question and one follow up. If you have additional questions, please rejoin the queue. I would now like to hand over to Christopher Stevo, Head of Investor Relations. Please go ahead.

speaker
Christopher Stevo
Head of Investor Relations

Thank you, Elliot. Good morning and good afternoon, everyone. Thank you for joining us for our third quarter earnings call. As usual, our materials are posted to our website this morning, so please feel free to see them there. And before I turn the call over to our CEO, Richard Francis, I'd like to remind everyone that we'll be making forward-looking statements on this call. The company cautions that investors that any forward-looking statement involves risks and uncertainties is not a guarantee of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. These factors are described in our earnings press release in our most recent forms, 10Q and 10K, filed with the FCC. Any statements that we make are only as of today, and we undertake no obligation to update those statements subsequently. However, I will now undertake the obligation to give you our CEO, Richard Francis.

speaker
Richard Francis
Chief Executive Officer

Thank you, Chris. Good morning, good afternoon, everybody. Thank you for joining the call. with me today on this call would be Dr. Eric Hughes, Head of Global R&D and Chief Medical Officer and Eli Kalif, CFO. Now moving on to the next slide, as always do I start with the Pivot to Growth Strategy and the four pillars. We launched it in 2023 and I'm going to give you an update in Q3 as the progress we've made against this strategy. Starting with deliver on our growth engines, we'll see that the innovative portfolio continues to perform well, instead of all delivering strong Q3 performance and our innovative portfolio is up 33% and we're raising full year guidance across all of these products. Now the importance of these products can be seen in our financials and you'll see that our revenue is stronger, our margins and our free cash flow also becomes stronger. Now looking to the second pillar, step up innovation, you see that we have eight major milestone readouts this year but also we've seen some good progress and the approval of Welch Reuser was a significant moment to Teva as well as the patients suffering from schizophrenia. We also have good progress in Ipipipan and we have FDA fast track designation for our NTR15 candidate for celiac disease. And so looking ahead we have four additional potential submissions over the next five years. With regard to an announcement we made earlier in the week, Emma Solman, After an independent data monitoring committee met on a pre-specified infant utility analysis, we have discontinued the Phase 2 study. As Greg pointed out, there were no safety concerns. Now, while this outcome was not what I had hoped for, and I'm deeply disappointed for the patients we are hoping to serve and the physicians who helped us on this journey, I'm particularly proud of the teams and the effort we've put into this program. What we have learned will take forward with even more determination. Now, another change to our and a pipeline that happened before the earnings was with regard to BioXcel and the acquisition of BXCL501. This is an asset we think is going to further strengthen our neuroscience franchise and our psychiatric portfolio. There's a big unmet medical need we believe in treating agitation at home and we think this in the hands of Teva could really help these patients with this unmet need. Now moving on to Sustained Genetics Powerhouse. Biosimilars you'll see throughout the presentation is becoming a significant growth driver for us now at Teva and our genetics business. We have 15 products on the market and 16 more in our pipeline and more opportunities to expand this. And actually, earlier today, you may have seen the press release that showed we have further strengthened our partnership with Samsung. We have two FDA-approved RT-TNFR for biosimilars. On the final pillar, on capital allocation, With the latest S&P upgrade, Tether has now achieved investment grade status across all three major rating agencies, reflecting the continued strength of our financial profile. We also, in this last quarter, refinanced 4.9 billion of senior notes. So please think about that. And then with regard to EDS conversions to ordinary shares in the New York Stock Exchange, we've now opened up the opportunity for broader investor access to Tether. So now starting with what I think was the highlight of Q3 for us, which was the launch of Welltrusa, the approval of Welltrusa. Now, this was a milestone for Teva, but more importantly, a milestone and an advancement between patients living with schizophrenia. Let's be clear, it starts with the patient. Schizophrenia is a devastating disease, and every relapse can have a significant impact on patients and their families. With Welltrusa, it brings a proven olanzapine efficacy in a once monthly subcutaneous are all injectable with the opportunity to help patients stay on treatment and reduce relapses. WALTUZA is the first and only long-acting injectable with no loading dose, no oral supplementation, or post-injection monitoring. And because of this, we believe WALTUZA can make a real difference for patients suffering from schizophrenia. So what is the opportunity? Well, on the next slide, you can see it's significant. With 2.2 million people who are diagnosed with schizophrenia in the US, approximately 1.7 million are treated and approximately 20% of the prescription are for oral olanzapine. We all know that olanzapine has a well-established efficacy and then safety profile and that is going to prove the strong foundation for Veltruza. But also, as we all agree, that our commercial organization is very well positioned to succeed with Veltruza, building on the great work that has been done over the last three years with your study. And I'll go into that in more detail later. But when you combine these two products, We have a portfolio designed to address a broad spectrum of unmet needs, which is setting what is highly differentiated and yet complementary. They're anchoring the two proven molecules of risperidone and olanzapine. And because of this, we have confidence in achieving the peak sales of 1.5 to 2 billion. But now let's move on to the financial. Now Q3 2026 reflects Tether's transition to a biopharma company. And the facts are in the numbers here. So let me walk you through that. So revenues declined 2%, but our gross margin grew to 58.7%. That's up 345 basis points. Our EBITDA grew 7%, and our non-GAAP EPS was up 10%. Now, I remember way back in 2023 when I presented the first quarter as CEO, and our gross margin was approximately 48%. So this really showed the substantial progress we've made in transitioning this company from a pure pay genetics to a biopharma company. Now, this isn't a one-quarter effect. It reflects deliberate choices we have made to transition the business. We set out in 2023 to become a biopharma company, and these results show that that transformation is happening. And what I'd highlight is there is more to come. Now, these results include IPR and D-impact, and Eliyahu will present and explain in a few minutes. Now, moving on to the next slide, our total revenues are $4.4 billion. Innovative was up 33% year-on-year, as I've mentioned. Esteda was up 21% globally at $751 million. Esteria was up 96% at $85 million. Najib was up 61% at $269 million. Generics were down 16%, and this was largely due to the low contribution of generic revenue. But now let me go into a bit more detail. So on to Esteda. Esteda reaches its $2.5 billion target one year ahead of schedule. I'm really, really proud of this and congratulations to the team for making this happen. So, revenues in the U.S. are up to $727 million, up 21%, and the fundamentals remain strong. U.S. TRX grew 18% and milligram dispense grew 23%. Now, given this strong momentum, we increased our outlook by $75 million at the midpoint, so our study will now be $2.55 billion to $2.65 billion. So congratulations to the team on that. I would like to highlight that the opportunity for Speda remains strong. You see that the market growth that can remain, new patients with 85% of patients not treated, you see a strong opportunity to keep growing this product to greater than 2 billion of the pre-sales as we previously communicated. Now moving on to your study. Your study is the fastest growing AI for schizophrenia. The revenues grew 96%. and the underlying demand remains strong, with TerraExit and MIT up 62% year-over-year. The excellent commercial execution is expanding the market, with the study nearly doubling with Spiridon-LAI's share from 5% to 10%, and capturing approximately 83% from Spiridon-LAI. It is worth noting that if you remember back 25, Q3 and Q4, we did have some one-off negative impacts, so it's worth keeping that in mind when you plan forward. That said, we're increasing our outlook on your study by 20 million at the midpoint. Now the range is 290 million to 310 million. It probably doesn't need pointing out, but I will, that this continued excellent execution gives us a solid foundation in which to launch what to use it. Now moving on to Adobe. GevExtend continues to extend its global leadership in migraine, continue to outperform the injectable market and lead in many markets where we have launched. Global revenue reached $269 million, up 61% year-over-year, with strong momentum across many markets. In the US, revenue grew 89%, while ex-US momentum remained strong, supported by volume growth as well as market share gain. Because of this strong momentum, we increased our average by $85 million at the midpoint, are raising it to $930 million and to $960 million. Now, I'd like to point out, this doesn't happen by chance. And if you remember, when we started on this journey in 2023, nobody was talking about Adjogu, but we reinvigorated it. And I think this reflects something broad about FedEx. We do things with intent, and we execute with intensity. And that's why looking beyond 2026, we see a path to greater than $1 billion of good sales for Adjogu. Now moving on to a couple of new products on our pipeline that I've touched upon earlier. Firstly, Ecopython. This is a first-in-class opportunity for Tourette's syndrome, combining compelling efficacy and favorable tolerability in a serious pediatric neurological disorder with limited treatment options. There are 100,000 pediatric patients who live with Tourette's syndrome every year. 50,000 are treated, but unfortunately, only 20% to 30% remain on therapy after one year. We hope to help that. and hope to help these patients and these children. Our next key milestone is obtaining regulatory approval, which we anticipate in Q1, 2027. Now moving on to the latest addition to our innovative pipeline is the asset that we acquired from Biocell, which is BXCL 501. Now this is expected to address another clear unmet need for patients experiencing acute agitation at home, extending our patient focus in neuroscience and bringing potential benefits to nearly 7 million patients. BXEL 501 could be the first at-home treatment for acute agitation and in regulatory approval, adding another differentiated opportunity and significant value to our neuroscience portfolio. This order also highlights another example of disciplined capital allocation, finding differentiated assets where Tether can have real value. Now, my colleagues will go into a bit more detail on Ecopython and BXEL 501 next week at our R&D day. Now, moving on to The next slide. When we talk about growth and we talk about the aggressive growth in Q3, it's worth pointing out that we have a decade-long runway of growth catalysts. And as you can see here, we have a maturing pipeline that I will talk about in more detail next week. But as you look at 2030 beyond, it really does get quite congested, this slide. And that's a great, exciting opportunity for Feather and for potential investors. Now moving on to the next slide, a slide which we've talked about for the last couple of years, But now we're starting to see some of these products actually come to the market. Obviously, we've spoken about Viltruza, we've spoken about the Netsam Opportunity, the QWAT, the EcoPipeBound. Now we've added BXF CL501. So we have a pipeline here that we are confident can deliver over 10 billion of sales going forward. But we'll give more detail on this at our R&D day next week. Now moving on to the generics business. Generic Powerhouse. are all going to have is resilient beyond Revlimid, which is exciting. And let me show the fundamentals that go with this. If you take away generic Revlimid, our global genetics business grew 1%, with the US down 3%, and EU up 7%, and emerging markets down 4%. Now, we expect our genetics business to be flat to slightly up in 2026, but we continue to be positive about long-term growth trajectory of this business, 1% to 2% over the long term. Now, I remain very optimistic about the future of our generic business. The main reason is the growth rate is really around our rapidly expanding biosimilar portfolio pipeline. So now if I move on to this, you will see this clearly on this slide. It's one of the fastest growing biosimilar businesses we have there. We set out to achieve 800 million of sales by 2027. Well, I'm in a position to tell you today that we're going to do that in 2026, a year ahead of schedule. and at the same time, we're expanding our portfolio from nine assets in 2024 to 15 today and potentially 18 in 2027. But it's worth noting, this is not simply about adding assets. We're deliberately shifting our portfolio towards biosimilar, an increasingly important growth driver for our genetic business. And what's important, it's not just about the portfolio, it's how we execute it. And as you can see, three out of the five US biosimilars are ranked number one, while in Europe, we are building leading positions across several important markets. If you go on to the next slide, we're going to continue on this journey, expanding our portfolio and bringing these biosimilars to markets in both the US and Europe. As you can see here, we have the potential to be 31 already, but I've also realized that this slide is already out of date because of the deal we announced today with Samsung, so it should be 32. So apologies for that, but it does really reflect the speed we move at at Teva. So based on this the Solid Foundation of Innovation and the Portfolio Transition of our Genetics Business with Biosimilars. I can move on to the next slide and say we are firmly on track to achieve our 2027 targets that we laid out back in 2023. And with that, I'm going to hand over to Eric.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API

Investor presentation